Roche has announced it is to acquire privately held healthcare and technology firm Flatiron Health for $1.9 billion to leverage the New York City firm’s technology and data analytics infrastructure, including its oncology-specific electronic health record software, to bolster its efforts in cancer research.
The deal to buy all of Flatiron’s shares follows Roche’s existing equity stake of 12.6% in the company, after it invested $175 million in 2016.
